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It is extremely difficult to establish human multiple myeloma (MM) cell lines,
especially from the bone marrow (1). Almost all myeloma cell lines reported have
been derived from extramedullary invasions of MM (1-4). Macrophage(MO) feeder
layers or Mo-conditioned media were successfully used for the culture of murine
plasmacytoma cells (5). Fibroblasts were also competent for long-term cultures of
human myeloma cells (1, 4). These facts suggest that bone marrow microenviron-
ments, especially MOs or fibroblasts, may play an important role in the growth of
myeloma cells through secreting growth factor(s)-
It is now known that B cell stimulatory factor 2, originally described as a T cell-de-
rived B cell differentiation factor, is identical to hybridoma plasmacytoma growth
factor, IFN-ß2, 26-kd protein, and hepatocyte stimulating factor (6-10), and is now
called IL-6. IL-6 is produced not only by T cells but also by M(Ds (10-13) or fibro-
blasts (7-9). M(Ds produce IL-6 in the absence of an apparent stimulus, although
T cells require antigen or mitogen stimulation for IL-6 production (12, 13).
These facts suggest that IL-6 produced by MOs or fibroblasts may support the
growth ofhuman myeloma cells. In this paper, we report that M(D-derived IL-6 aug-
ments the growth of myeloma cell lines, and both cell lines, ILKM2 and ILKM3,
can be maintained in vitro in RPMI 1640 with 8% FCS and rIL-6.
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Human Myeloma Cell Lines (ILKM2 and ILKM3).
￿
The cultures were initiated on July 8,
1986 for ILKM2 and October 7, 1986 for ILKM3 from the bone marrow aspirates ofpatients
with MM, IgG-K type. They are now being maintained in RPMI 1640 with 8% FCS, 100
wg/ml piperacillin, and 2 ng/ml rIL-6 with incomplete medium change every 4 d.
Reagents.
￿
The sources ofrIL-la, rIL-lß, rIL-2, rIL-3, rIL-4, rIFN-a, native IFN-ß (nIFN-
0), rIFN-y, rTNRa, recombinant granulocyte/macrophage CSF (rGM-CSF), rG-CSF, recom-
binant epidermal growth factor (rEGF), and mAbs are described elsewhere (13, 14). Poly-
clonal anti-IL-6 (a-IL-6) antibody and rIL-6 were generously provided by Drs. T. Hirano
and T. Kishimoto of Osaka University (6, 15). The sp act of the rIL-6 is 5 x 106 U/mg of
protein.
ProductionofMO-derivedFactors (MDF).
￿
The proceduresto obtain Mos and MDF are de-
scribed elsewhere (14). MDF used in this experiment has IL-6 and IL-1 activity but no IL-2
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or IFN-y (13, 14) . Partially purified MDF (pMDF) was prepared by using Sephadex G-100
chromatography. Active fractions on myeloma cell growth, whose apparent mol wt was 26,000,
were used as pMDF.
ProliferativeAssays .
￿
Myeloma cells were washed and resuspended inRPMI 1640 with 8%
FCS and 100 gg/ml piperacillin . A quantity of 10 4 cells was plated in 96-well flat-bottomed
microplates and stimulated with MDF, various cytokines, or M(bs . For the inhibition assay
using a-IL-6 antibody, MDF or recombinant cytokines were preincubated with a-IL-6 anti-
body (10 Itg/ml) for 1 h at 37°C and then myeloma cells were added to the culture . The cul-
ture was incubated for 96 h and pulsed for a final 24 h with 0.5 gCi [''H]thymidine .
['H]Thymidine incorporation was determined by scintillation counting.
Characterization ofMyeloma Cell Lines.
￿
The methods for morphological analysis and cell
surface marker analysis are described elsewhere (14) .
Results
Establishment and Characterization of Cell Lines .
￿
For the first 3 mo of the long-term
cultures, myeloma cells proliferated very slowly on bone marrow-derived M(Ds and/or
fibroblasts . 3 mo later, these cells could be transferred to the wells that were feeder
layered with allogeneic MIN . They could also be maintained in the medium con-
taining MDF and then in the medium containing 2 ng/ml rIL-6 . Both cell lines,
named ILKM2 and ILKM3, had the typical morphological features of myeloma
cells as shown in Fig . 1 . The surface phenotype of both cells was PCA-1 + , OKT10 + ,
CD10- , CD19- , CD20- , CD21 - , and OKIa-1 - , showing a typical myeloma cell
phenotype. Cytoplasmic Ig staining showed that IgG-K was positive in ILKM2 and
only K chain was positive in ILKM3 . EBV nuclear antigen (EBNA) was negative
in both cell lines . The population doubling time was 120 h for ILKM2 and 96 h
for ILKM3, when they were cultured in the medium containing 2 ng/ml rIL-6 .
Proliferation ofILKM2 or ILKM3.
￿
ILKM2 and ILKM3 did not proliferate spon-
taneously. They proliferated vigorously in the presence of allogeneic MOs (Fig. 2,
A and D) . MDF could substitute for the MO functions and induced the growth of
myeloma cell lines in a dose-dependent manner (Fig. 2, Band E) . Among the cytokines
examined, IL-6 had the strongest activity on the DNA synthesis in both cell lines
(Fig . 3) . rIL-6, even at the dose of 0.05 ng/ml, had significant growth-enhancing
FIGURE 1 .
￿
The morphology of
two established cell lines . May-
Giemsa staining shows the typ-
ical plasmacytoid features of
both cell lines, ILKM2 (A) and
ILKM3 (B) .A
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FIGURE 2 . Proliferative responses of
ILKM2 (A, B, andC) andILKM3 (D, E,
and F) to addedmacrophages (A andD),
MDF (B and E), or rIL-6 (C and F) . A
quantity of 10 4 myeloma cells was cul-
tured with various concentrations of mac-
rophages, MDF, or rIL-6, and the DNA
synthesis was measured as described in
MaterialsandMethods . Medium control
experiments (O) ; DNA synthesis in mac-
rophages alone (/) .
activity (Fig . 2, C and F) . IL-1a, IL-1ß, IFN-a and, to a lesser extent, TNFa also
had growth-enhancing activity on ILKM2, however, these active factors were not
competent for the maintenance of ILKM2 . ILKM3 proliferated only in response
to IL-6 orMDF (Fig . 3) . These results suggested that the myeloma cell growth ac-
tivity in MDF was derived from IL-6 for the most part .
Inhibition ofMyeloma Cell Growth by a-IL-6Antibody .
￿
a-IL-6 antibody completely in-
hibited rIL-6-dependent growth ofILKM2 andILKM3 (Table I) . It also completely
inhibited MDFdependent growth ofILKM2 . Anti-IL-6 antibody only partially in-
hibited MDFinduced proliferation of ILKM3, but almost completely inhibited
FIGURE 3 . Proliferative re-
sponses of ILKM2 (A) and
ILKM3 (B) to various recom-
binant cytokines . Aquantity of
10 4 myeloma cells was cultured
with various cytokinesand the
DNA synthesis was measured
as described in Materials and
Methods. The concentrations of
cytokines used in these experi-
ments were as follows : IL-1a,
2-20 ng/ml (20) ; IL-lß, 2-20
ng/ml (20) ; IL-2, 0.25-2.5
ng/ml (2.5) ; IL-3, 1-10 U/ml
(10); IL-4, 2-20 U/ml (20) ; IL-
6, 0.4-4 ng/ml (4); IFN-a,
100-1,000 U/ml (100) ; IFN-p,
100-1,000 U/ml (100) ; IFN-y,
100-1,000 U/ml (100) ; G-CSF,
0.25-2.5 ng/ml (2.5) ; GM-CSF,
0.25-2.5 ng/ml (2.5); EGF,
10-100 ng/ml (100); andMDF,
5-50% (50) . [3H]Thymidine
uptake shows themaximum re-
sponse in thosedose ranges .The
dose of each cytokine described
in parentheses was used in the
experiments shown in Fig. 3 . (*)
Native, fibroblast-derived IFN-
ß was used in this experiment.342
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TABLE I
Effect of Anti-IL-6 Antibody on DNA Synthesis in Myelorna Cell Lines
Induced by rIL-6 MDF, or pMDF
Anti-IL-6 antibody (10 4g/ml) or normal rabbit IgG (control IgG, 10 erg/ml) was preincubated with MDF,
pMDF, or rIL-6 at 37°C for 1 h and the DNA synthesis in ILKM2 or ILKM3 was measured as described
in Materials and Methods. MDF, macrophage culture supernatant; pMDF, partially purified MDF (active
fractions on myeloma cell growth, 26 kD), separated by Sephadex G-100 chromatography.
pMDFinducedproliferation ofILKM3. Theseresultsindicatedthat IL-6 is thepri-
mary myeloma cell growth factor included in the MDF.
Discussion
In this report, we demonstrated that twobone marrow-derived myelomacell lines
proliferate dependentlyon MO feeder layers, MDF or rIL-6, and that both cell lines
have been maintained in vitro in the medium containing rIL-6 for >1 yr.
Although autocrine mechanisms of myeloma cell growth have been documented
by several authors (16, 17), theestablishment of spontaneouslyproliferating myeloma
cell lines in vitro is extremely difficult (1). In addition to autocrine mechanisms,
paracrine mechanisms have also been suggested to play an important role in my-
eloma cell growth (1, 4, 18, 19). Our results agree with the paracrine mechanisms
of myeloma cell growth; bone marrow-derived myelomacell lines proliferate in the
presence of MOs, MDF is able to substitute for the M(b functions, Mos produce
IL-6, myeloma cell lines most strongly proliferate in response to rIL-6, a-IL-6 anti-
body inhibits the rIL-6- or MDFinduced proliferation of myeloma cell lines, and
myeloma cell lineshave been maintained for>1 yr in the medium containing rIL-6.
Furthermore, two other bone marrow-derived myeloma cell lines have now been
maintained for >6 mo by using MO feeder layers (unpublished observation). This
indicates that our method is reproducibly applicable for establishing myeloma cell
lines. All this evidence, as well as the fact that MO is a constituent of bone marrow
stromal cells, suggests that M(bs, through secretingIL-6, play a key role in the growth
of myeloma cells in vivo. In accordance with our results, Nordan and Potter (19)
demonstrated that murine plasmacytoma haddeveloped exclusively from themineral
Reagent
added
Antibody
added ILKM2
[3H]Thymidine uptake
ILKM3 (Exp. 1) ILKM3 (Exp. 2)
mean cpm ± SD
Medium - 4,941 f 423 805 ± 203 5,270 ± 321
Medium Anti-IL-6 4,160 t 367 943 ± 142 5,826 t 348
Medium Control IgG 4,826 t 235 1,005 ± 132 ND
IL-6 (0.4 ng/ml) - 16,355 ± 451 8,317 ± 276 19,866 ± 820
IL-6 (0.4 ng/ml) Anti-IL-6 4,320 ± 102 1,475 f 121 3,363 ± 424
IL-6 (0.4 ng/ml) Control IgG 15,788 f 899 8,482 f 761 ND
IL-6 (0.2 ng/ml) - 9,575 ± 88 5,482 ± 467 8,160 f 377
IL-6 (0.2 ng/ml) Anti-IL-6 4,175 ± 367 1,246 ± 260 3,976 ± 274
IL-6 (0.2 ng/ml) Control IgG 10,073 ± 434 7,135 ± 652 ND
MDF (25%) - 13,043 ± 387 6,055 f 421 17,088 t 97
MDF (25%) Anti-IL-6 4,659 t 367 4,751 ± 214 13,749 ± 75
MDF (25%) Control IgG 14,092 t 583 6,984 ± 466 ND
pMDF (25%) - ND 10,373 f 234 ND
pMDF (25%) Anti-IL-6 ND 3,765 ± 223 ND
pMDF (25%) Control IgG ND 12,975 t 1,687 NDSHIMIZU ET AL.
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oil-induced granulomatous tissue composed of M(bs and neutrophils and the M(D-
derived factor, which is now known to be identical to IL-6, was able to maintain
mouse plasmacytoma cells in vitro. Since it was reported that IL-6 is an autocrine
growth factor for human muliple myeloma (16), both autocrine and paracrine
mechanims, mediated through IL-6, may be involved in the in vivo growth of my-
eloma cells.
The proliferative response of ILKM2 to IL-la, IL-lß, and IFN-ais also interesting.
Another myeloma cell line (KMI) and several fresh myeloma cells also proliferate
in response to IL-1 (unpublished observation). Furthermore, in addition to IL-6,
ILKM3 appears to proliferate in response to a monokine or monokines that are
different from the known monokines examined (Fig. 3 andTable I). IL-1 and TNF
a are knownto induce IL-6 secretion from fibroblasts (7-9). Although we could not
detect IL-6 activity in the culture supernatant of both cell lines when they were cul-
tured with various mitogens or cytokines, a possibility that IL-6 produced by my-
eloma cells binds to their own IL-6-Rs immediately after secretion is not excluded.
Whether IL-1, IFN-a, or other unknown factors induce IL-6 secretion from my-
elomacells, and whether another myeloma cell growth factor exists or not, remains
to be elucidated in the future.
Ourdata imply that MOs or IL-6 can be uesd to establish bone marrow-derived
myeloma cell linesmore efficiently and that myeloma cells established could be used
forthe analysis ofmyeloma cell growth regulation by cytokinesor drugs. These studies
may open up a new approach to the treatment of MM.
Summary
Two IL-6-dependent human multiple myeloma cell lines, ILKM2 and ILKM3,
were established from the bone marrow of patients with IgG-K multiple myeloma.
Both cell lines had the typical morphology and immunocytochemical features of
myeloma cells. The surface phenotype of both cell lines was PCA-1+ , OKT10+,
CD10(J-5)- , CD19(B4)-, CD20(Bl)- , CD21(B2)- , and OKIa-1 - . A monoclonal
cytoplasmic Ig, IgG-K or K L chain, was positive in ILKM2 or ILKM3, respec-
tively. EBV nuclear antigen was negative in both cell lines. They proliferated in the
presence ofmacrophagesor macrophage-derived factors (MDF). Amongthe recom-
binant cytokines examined, IL-6 most strongly augmented the growth of both cell
lines. The anti-IL-6 antibody completely inhibited the IL-6-dependent growth and
almost completely inhibited the MDF or purified MDF-dependent growth of both
cell lines. ILKM2 and ILKM3 are now being maintained in the culture medium
containing 2 ng/ml rIL-6.
These results suggest that IL-6 produced by macrophagesmayplay an important
role in the growth of myeloma cells in vivo and that macrophages or IL-6 can be
used for establishing human myeloma cell lines.
Receivedfor publication 5 July 1988 and in revisedform 23 September 1988.
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